Published in Hepatitis Weekly, June 2nd, 1997
Termed Oragen drugs, the compounds are low molecular weight RNA designer drugs which the company believes have the potential to become the first oral, broad-spectrum treatment for various major viral diseases. In some parts of the world, more than 20 percent of the populations are infected with these diseases. Results from in vitro studies conducted in collaboration with the National Institute of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.